ZuriEV
Z├╝rich
About ZuriEV
ZuriEV is a University of Zurich spin-off developing a highly sensitive, non-invasive blood-based diagnostic platform for early detection and monitoring of brain cancers. Their liquid biopsy technology isolates tumor-specific extracellular vesicles (EVs) from blood using proprietary biomarkers, enabling accurate and scalable cancer detection and monitoring.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Total funding: $183.8K
- Last round: Grant (Jun 2025)
- Website: zuriev.com
Industries & Categories
Biopharma, Medical, Medical Device
Canonical: https://fsome.com/organization/zuriev-13649 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.